Literature DB >> 2110464

Elevated white blood cell synthesis of leukotriene C4 in chronic myelogenous leukaemia but not in polycythaemia vera.

L Stenke1, J Samuelsson, J Palmblad, L Dabrowski, P Reizenstein, J A Lindgren.   

Abstract

Leukotriene (LT) formation was studied in ionophore A23187-stimulated white blood cell (WBC) preparations from patients with chronic myelogenous leukaemia (CML; n = 14), polycythaemia vera (PV; n = 10) and two control groups consisting of patients with non-malignant inflammatory disease (n = 4) and normal healthy donors (n = 25). The synthesized products were identified and quantitated using high-performance liquid chromatography combined with computerized UV-spectroscopy. White blood cell preparations from the CML patients produced more LTC4 (40.2 +/- 7.9 pmol/10(6) WBC, mean +/- SEM) than WBC from the healthy donors (9.0 +/- 1.8), P less than 0.0005. In contrast, the formation of LTB4 was normal and there was no increase in the total leukotriene synthesis (the sum of LTC4, LTB4, 20-OH-LTB4 and the delta 6-trans-isomers of LTB4). The ratio between leukotrienes C4 and B4 was strongly elevated in the CML group; 1.67 +/- 0.25 v. 0.37 +/- 0.07 in the controls, P less than 0.0005. No significant correlation was observed between the levels of LTC4 and the number of known LTC4 producing cells (such as monocytes, eosinophils and basophils) in the CML WBC preparations. In contrast, a correlation was found between the sum of neutrophilic granulocytes and metamyelocytes in these suspensions and the amount of LTB4 formed; r = 0.600, P less than 0.05. A number of other laboratory or clinical variables of the CML patients (including total white blood cell and platelet counts, differential counts, previous cytotoxic treatment, time from diagnosis, time from last treatment, post study survival and age) did not significantly correlate with the formation of leukotrienes. No abnormality in the production of LTB4 or LTC4 was observed in granulocyte and WBC preparations from the patients with polycythaemia vera and non-malignant inflammatory disease, respectively. The results indicate a selectively increased LTC4 producing capacity in CML.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2110464     DOI: 10.1111/j.1365-2141.1990.tb02580.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  4 in total

1.  Regulation of granulocytosis in inflammatory disease and in leukemia.

Authors:  P Reizenstein; L Stenke
Journal:  Med Oncol Tumor Pharmacother       Date:  1993

2.  Leukotrienes promote stem cell self-renewal and chemoresistance in acute myeloid leukemia.

Authors:  Alec W Stranahan; Iryna Berezniuk; Sohini Chakraborty; Faye Feller; Mona Khalaj; Christopher Y Park
Journal:  Leukemia       Date:  2022-04-23       Impact factor: 12.883

3.  Identification of 12/15-lipoxygenase as a suppressor of myeloproliferative disease.

Authors:  Melissa Kristine Middleton; Alicia Marie Zukas; Tanya Rubinstein; Michele Jacob; Peijuan Zhu; Liang Zhao; Ian Blair; Ellen Puré
Journal:  J Exp Med       Date:  2006-10-16       Impact factor: 14.307

Review 4.  Cysteinyl Leukotriene Pathway and Cancer.

Authors:  Ming-Ju Tsai; Wei-An Chang; Cheng-Hao Chuang; Kuan-Li Wu; Chih-Hung Cheng; Chau-Chyun Sheu; Ya-Ling Hsu; Jen-Yu Hung
Journal:  Int J Mol Sci       Date:  2021-12-23       Impact factor: 5.923

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.